KR890006226A - 신규 약제 및 그의 제조 방법 - Google Patents

신규 약제 및 그의 제조 방법 Download PDF

Info

Publication number
KR890006226A
KR890006226A KR1019880013076A KR880013076A KR890006226A KR 890006226 A KR890006226 A KR 890006226A KR 1019880013076 A KR1019880013076 A KR 1019880013076A KR 880013076 A KR880013076 A KR 880013076A KR 890006226 A KR890006226 A KR 890006226A
Authority
KR
South Korea
Prior art keywords
metoprolol
dihydropyridine
formulation
castor oil
water
Prior art date
Application number
KR1019880013076A
Other languages
English (en)
Other versions
KR960009411B1 (en
Inventor
앤더스 라그나트손 게르트
마르가례라 실프베르스트란드 카사
앨버트 스외그텐 존
Original Assignee
앤더스 베딘
악티에볼타게트 헤슬레
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20369795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR890006226(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 앤더스 베딘, 악티에볼타게트 헤슬레 filed Critical 앤더스 베딘
Publication of KR890006226A publication Critical patent/KR890006226A/ko
Application granted granted Critical
Publication of KR960009411B1 publication Critical patent/KR960009411B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

신규 약제 및 그의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 건가안 피실험자에 단일 투여량을 투여한 후 혈장에서 펠로디핀의 평균 농도를 나타낸 그래프임.

Claims (11)

  1. 메토프롤롤을, 가용성 주성분으로서 수불용성 중합체막으로 피복시킨 메토프롤롤의 염을 함유하는 소형 비드의 형태에 포함시키고, 디히드로피리딘을 비이온계 가용화제 중에 분산시킴으로써, 분산된 디히드로피리딘과 메토프롤롤을 함유하는 비드를 모두 물과 접촉하여 팽윤겔을 형성하는 매트릭스에 혼입시키는 것을 특징으로 하는, 메토프롤롤 및 디히드로피리딘 종류의 불충분한 수용성 칼슘 통로 차단계의 배합물을 함유하는 1일 1회 투여용 지속제 제제.
  2. 제1항에 있어서, 비이온계 가용화제가 폴리에톡실화피마자유, 폴리에톡실화 수소 첨가 피마자유, 피마자유에서 얻은 폴리에톡실화 지방산 또는 첨가 피마자유에서 얻은 폴리에톡실화 지방산 군 중에서 선택된 것을 특징으로 하는 제제.
  3. 제1항에 있어서, 비이온계 가용화제가 수소 첨가피마자유 지방산과 옥시에틸화 글리세린과의 에스테르인 것을 특징으로 하는 제제.
  4. 제1항에 있어서, 디히드로피리딘이 펠로디핀인 것을 특징으로 하는 제제.
  5. 제1항에 있어서, 디히드로피리딘이 니페디핀인 것을 특징으로 하는 제제.
  6. 제1항에 있어서, 겔-형성 매트릭스가 히드록시프로필 메틸셀룰로오스를 함유하는 것을 특징으로 하는 제제.
  7. 제1항에 있어서, 메토프롤롤이 그의 숙신산염 형태인 것을 특징으로 하는 제제.
  8. 제1항에 있어서, 디히드로피리딘의 2.5mg 내지 80mg 사이에서 변화시키고, 메토프롤롤 숙신산염 라세미체의 양을 40mg 내지 200mg 사이에서 변화시키는 것을 특징으로 하는 제제.
  9. 제1항에 있어서, 메토프롤롤이 S-에난티오머의소르브산염 형태이며, 양을 25mg 내지 120mg 사이에서 변화시키는 것을 특징으로 하는 제제.
  10. 제1항에 있어서, 메토프롤롤이 메토프롤로의 S-에난티오머의 벤조산염 또는 소르브산염 형태인 것을 특징으로 하는 제제.
  11. 메토프롤롤을, 가용성 주성분으로서 메토프롤로의 염을 함유하는 소형 비드의 형태에 포함시키고, 이 비드를 양성자 전이기가 없는 셀룰로오스의 유도체를 함유하는, 수불용성 중합체 막으로 분무 피복시키고, 디히드로 피리딘을 비이온계 가용화제 중에 분산시킨 후, 비드와 디히드로피리딘을 모두 물과 접촉하여 팽윤 겔을 형성하는 매트릭스에 혼입시키는 것을 특징으로 하는, 케토프롤롤 및 디히드로피리딘 종류의 불충분한 수용성 칼슘 통로 차단제의 배합물을 함유하는 지속성 제제의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR88013076A 1987-10-08 1988-10-07 Controlled release preparation containing metoprolol and dihydropyridine KR960009411B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8703881-6 1987-10-08
SE8703881A SE8703881D0 (sv) 1987-10-08 1987-10-08 New pharmaceutical preparation

Publications (2)

Publication Number Publication Date
KR890006226A true KR890006226A (ko) 1989-06-12
KR960009411B1 KR960009411B1 (en) 1996-07-19

Family

ID=20369795

Family Applications (1)

Application Number Title Priority Date Filing Date
KR88013076A KR960009411B1 (en) 1987-10-08 1988-10-07 Controlled release preparation containing metoprolol and dihydropyridine

Country Status (26)

Country Link
US (1) US4942040A (ko)
EP (1) EP0311582B1 (ko)
JP (1) JP2619936B2 (ko)
KR (1) KR960009411B1 (ko)
CN (1) CN1029935C (ko)
AT (1) ATE84412T1 (ko)
AU (1) AU615211B2 (ko)
CA (1) CA1312286C (ko)
CY (1) CY1896A (ko)
DE (1) DE3877492T2 (ko)
DK (1) DK175085B1 (ko)
ES (1) ES2053815T3 (ko)
FI (1) FI92903C (ko)
GR (1) GR3006788T3 (ko)
HK (1) HK6296A (ko)
HU (1) HU210461A9 (ko)
IE (1) IE63084B1 (ko)
IL (1) IL87922A (ko)
IS (1) IS1584B (ko)
MX (1) MX169243B (ko)
MY (1) MY104065A (ko)
NO (1) NO177375C (ko)
NZ (1) NZ226245A (ko)
PH (1) PH25568A (ko)
PT (1) PT88711B (ko)
SE (1) SE8703881D0 (ko)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268182A (en) * 1988-06-24 1993-12-07 Abbott Laboratories Sustained-release drug dosage units of terazosin
GB9025251D0 (en) * 1990-11-20 1991-01-02 Solomon Montague C Nifedipine dosage forms
DE69212646T2 (de) * 1991-03-18 1997-03-13 Sepracor Inc Zubereitung und verfahren enthaltend optisch reines s-metoprolol
US5834496A (en) * 1991-12-02 1998-11-10 Sepracor, Inc. Methods for treating hypertension using optically pure S(-) felodipine
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US5399358A (en) * 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
US5399362A (en) * 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
AU705378B2 (en) * 1994-04-25 1999-05-20 Penwest Pharmaceuticals Co. Sustained release excipient
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
WO1997026865A1 (en) * 1996-01-29 1997-07-31 Edward Mendell Co., Inc. Sustained release excipient
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
MX9801835A (es) 1996-07-08 1998-08-30 Mendell Co Inc Edward Matriz de liberacion sostenida para medicamentos insolubles de dosis altas.
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
ATE424810T1 (de) * 1998-12-11 2009-03-15 Nostrum Pharmaceuticals Inc Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
CA2352211C (en) 1999-09-30 2009-03-24 Edward Mendell Co., Inc. Sustained release matrix systems for highly soluble drugs
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
CZ301790B6 (cs) * 2000-04-11 2010-06-23 Sankyo Company Limited Farmaceutický prípravek obsahující blokátor vápníku
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
WO2002036099A1 (en) 2000-10-30 2002-05-10 Euro-Celtique S.A. Controlled release hydrocodone formulations
CN1268338C (zh) * 2001-07-06 2006-08-09 恩德制药公司 用作止痛剂的6－羟基羟吗啡酮的口服给药
WO2003024428A1 (en) * 2001-09-14 2003-03-27 Scolr, Inc. Amino acid modulated extended release dosage form
US20040009220A1 (en) * 2001-12-31 2004-01-15 Vinay Sharma Rate-controlled beta blockers and process for forming same
CA2481091A1 (en) * 2002-04-05 2003-10-23 Penwest Pharmaceuticals Co. Sustained release metoprolol formulations
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
US20080051428A1 (en) * 2002-05-15 2008-02-28 Davis Paul J Pyrroloquinoline quinone drugs and methods of use thereof
US20050267143A1 (en) * 2002-05-15 2005-12-01 Davis Paul J Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
US7276514B2 (en) * 2002-05-15 2007-10-02 Charitable Leadership Foundation - Medical Technology Acceleration Program Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
KR20030095600A (ko) * 2002-06-12 2003-12-24 환인제약 주식회사 펠로디핀을 포함하는 제어방출형 조성물 및 그 제조방법
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
US20070092573A1 (en) * 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
TW200806648A (en) * 2005-11-29 2008-02-01 Sankyo Co Acid addition salts of dihydropyridine derivatives
TW200736245A (en) * 2005-11-29 2007-10-01 Sankyo Co Acid addition salts of optically active dihydropyridine derivatives
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
EP2255791B1 (en) * 2009-04-03 2011-11-16 Zaklady Farmaceutyczne Polpharma SA Extended release pharmaceutical composition comprising metoprolol succinate
AU2011253216B2 (en) * 2010-05-11 2016-10-20 Cima Labs Inc. Alcohol-resistant formulations
MX2012012991A (es) * 2010-05-11 2012-11-30 Cima Labs Inc Formas de dosificacion oral de liberacion prolongada resistentes al alcohol y que contienen metoprolol.
AU2012303683B2 (en) * 2011-08-26 2016-09-08 Wockhardt Limited Methods for treating cardiovascular disorders
GB2512059B (en) * 2013-03-18 2016-08-31 Rolls Royce Plc An independently moveable machine tool
CN113143877A (zh) * 2021-05-07 2021-07-23 苏州康恒研新药物技术有限公司 一种琥珀酸美托洛尔微丸缓释片的制备方法
CN114712319B (zh) * 2022-03-25 2024-01-09 北京诺康达医药科技股份有限公司 一种非洛地平盐酸普萘洛尔复方制剂及其制备方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
CH532038A (de) * 1970-05-25 1972-12-31 Ciba Geigy Ag Verfahren zur Herstellung von neuen Cycloheptenderivaten
US3951821A (en) * 1972-07-14 1976-04-20 The Dow Chemical Company Disintegrating agent for tablets
US4123382A (en) * 1973-05-25 1978-10-31 Merck & Co., Inc. Method of microencapsulation
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
SE418247B (sv) * 1975-11-17 1981-05-18 Haessle Ab Sett att framstella kroppar med reglerad frigoring av en aktiv komponent
US4016880A (en) * 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4291016A (en) * 1976-07-27 1981-09-22 Sandoz Ltd. Enteric coated mixture of 4-(2-hydroxy-3-isopropylamino-propoxy) indole and sodium lauryl sulphate
GB1542414A (en) * 1976-08-19 1979-03-21 Standard Telephones Cables Ltd Arrangements for the controlled release of biologically active materials
DE2642032A1 (de) * 1976-09-18 1978-03-30 Merck Patent Gmbh Siliciumdioxidhaltige zubereitungen und verfahren zu ihrer herstellung
GB1576376A (en) * 1977-03-30 1980-10-08 Benzon As Alfred Multiple-unit drug dose
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
SE426548B (sv) * 1978-12-05 1983-01-31 Haessle Ab Fast farmaceutisk beredning innehallande en terapeutiskt effektiv hjertglykosid och en polymer
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4357469A (en) * 1979-06-14 1982-11-02 Forest Laboratories, Inc. Carrier base material for prolonged release therapeutic compositions
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4309406A (en) * 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
CH655658B (ko) * 1980-09-18 1986-05-15
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4439195A (en) * 1980-10-14 1984-03-27 Alza Corporation Theophylline therapy
US4428883A (en) * 1981-03-06 1984-01-31 The University Of Kentucky Research Foundation Novel method of administering β-blockers and novel dosage forms containing same
IT1144911B (it) * 1981-03-19 1986-10-29 Pharmatec Spa Composizione farmaceutica a rilascio controllato contenente ibuprofen
GB2098867B (en) * 1981-05-21 1984-10-24 Wyeth John & Brother Ltd Sustained release pharmaceutical composition
JPS57209223A (en) * 1981-06-19 1982-12-22 Tanabe Seiyaku Co Ltd Microcapsule for intracranial anti hypotension and its production
US4369272A (en) * 1981-07-07 1983-01-18 E. I. Du Pont De Nemours And Company Process for preparing polyolefin resin extended pigments comprising salt milling crude pigment with the resin
US4484921A (en) * 1982-02-01 1984-11-27 Alza Corporation Theophylline therapy utilizing osmotic delivery
US4649043A (en) * 1982-03-22 1987-03-10 Alza Corporation Drug delivery system for delivering a plurality of tiny pills in the gastrointestinal tract
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4642233A (en) * 1982-03-22 1987-02-10 Alza Corporation Gastrointestinal drug delivery system comprising a hydrogel reservoir containing a plurality of tiny pills
JPS58170712A (ja) * 1982-03-31 1983-10-07 Chiyoda Yakuhin Kk インドメタシン徐放錠
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
DE3247118A1 (de) * 1982-12-20 1984-06-20 Cassella Ag, 6000 Frankfurt Neue substituierte 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4681583A (en) * 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
US4578075A (en) * 1982-12-20 1986-03-25 Alza Corporation Delivery system housing a plurality of delivery devices
DE3307422A1 (de) * 1983-03-03 1984-09-06 Bayer Ag, 5090 Leverkusen Fluessigzubereitungen von dihydropyridinen, ein verfahren zu ihrer herstellung, sowie ihre verwendung bei der bekaempfung von erkrankungen
PH18946A (en) * 1983-04-21 1985-11-14 Elan Corp Plc Controlled absorption pharmaceutical composition
GB2146531B (en) * 1983-09-15 1987-04-29 Stc Plc Controlled release system
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
DE3586600T2 (de) * 1984-02-10 1993-02-18 Benzon Pharma As Dosierungsform eine vielzahl mit einer diffusionshuelle ueberzogener einheiten enthaltend.
GB2154874B (en) * 1984-02-29 1987-11-04 Sandoz Ltd Bromoscriptine compositions
IT1206166B (it) * 1984-07-26 1989-04-14 Sigma Tau Ind Farmaceuti Dispositivo per rilasciare una sostanza in un fluido di dissoluzione con cinetica di ordine zero e procedimento per la sua preparazione
DE3419131A1 (de) * 1984-05-23 1985-11-28 Bayer Ag, 5090 Leverkusen Dihydropyridinkombinationspraeparate und verfahren zu ihrer herstellung
US4794111A (en) * 1984-05-23 1988-12-27 Bayer Aktiengesellschaft Dihydropyridine preparations containing β-blockers
GB2159715B (en) * 1984-06-04 1988-05-05 Sterwin Ag Pharmaceutical composition in sustained release unit dose form and process for its preparation
SE455836B (sv) * 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
US4808413A (en) * 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method

Also Published As

Publication number Publication date
IS3398A7 (is) 1989-04-09
NZ226245A (en) 1990-08-28
NO177375C (no) 1995-09-06
CY1896A (en) 1996-09-27
FI884636A0 (fi) 1988-10-07
DE3877492T2 (de) 1993-05-13
PH25568A (en) 1991-08-08
CA1312286C (en) 1993-01-05
IE63084B1 (en) 1995-03-22
US4942040A (en) 1990-07-17
NO884269D0 (no) 1988-09-27
CN1032490A (zh) 1989-04-26
CN1029935C (zh) 1995-10-11
IL87922A (en) 1993-07-08
FI92903C (fi) 1995-01-25
JP2619936B2 (ja) 1997-06-11
GR3006788T3 (ko) 1993-06-30
KR960009411B1 (en) 1996-07-19
SE8703881D0 (sv) 1987-10-08
NO177375B (no) 1995-05-29
DE3877492D1 (de) 1993-02-25
MX169243B (es) 1993-06-25
EP0311582A1 (en) 1989-04-12
MY104065A (en) 1993-11-30
AU615211B2 (en) 1991-09-26
FI92903B (fi) 1994-10-14
PT88711B (pt) 1992-12-31
ES2053815T3 (es) 1994-08-01
DK558688D0 (da) 1988-10-06
FI884636A (fi) 1989-04-09
JPH01128917A (ja) 1989-05-22
IL87922A0 (en) 1989-03-31
DK175085B1 (da) 2004-05-24
IE882921L (en) 1989-04-08
NO884269L (no) 1989-04-10
HU210461A9 (en) 1995-04-28
DK558688A (da) 1989-04-09
HK6296A (en) 1996-01-19
EP0311582B1 (en) 1993-01-13
ATE84412T1 (de) 1993-01-15
AU2237488A (en) 1989-04-13
IS1584B (is) 1996-03-01

Similar Documents

Publication Publication Date Title
KR890006226A (ko) 신규 약제 및 그의 제조 방법
CA1204671A (en) Controlled release naproxen and naproxen sodium tablets
US4483846A (en) Long-lasting three-layered pharmaceutical film preparations
Taylan et al. Design and evaluation of sustained-release and buccal adhesive propranolol hydrochloride tablets
DE69826290T2 (de) Pharmazeutische zusammensetzungen zur kontrollierten freigabe von wirkstoffen
AU632655B2 (en) Method for percutaneous delivery of ibuprofen using hydroalcoholic gel
KR100551930B1 (ko) 경피 전달계
AU754490B2 (en) Topical hormonal composition with systemic effect
DE69212710T2 (de) Pharmazeutische Zusammensetzung mit kontrollierter Freigabe und bioadhäsiven Eigenschaften
JP2535339B2 (ja) 活性物質の制御速度制御用装置
EP0250374B1 (en) Therapeutic system for controlled release of drugs
JPH0778016B2 (ja) 徐放性を有する新規医薬製剤
DE202006018608U1 (de) Buprenorphin-Wafer zur Drogensubstitutionstherapie
MX2012007062A (es) Composición novedosa de hidrogel transdérmico de dexibuprofeno.
US6528090B2 (en) Controlled release formulation of divalproex sodium
US20040156897A1 (en) Controlled release formulation of divalproex sodium
US6713086B2 (en) Controlled release formulation of divalproex sodium
KR880000090A (ko) 서방형 이부프로펜 제제의 제조방법
WO2004096186A1 (en) Extended release venlafaxine tablet formulation
Gondaliya et al. The fabrication and evaluation of the formulation variables of a controlled-porosity osmotic drug delivery system with diltiazem hydrochloride
US20020025341A1 (en) Controlled release formulation of divalproex sodium
Dahl et al. Effects of various granulating systems on the bioavailability of naproxen sodium from polymeric matrix tablets
CA2295646A1 (en) Delivery of hypericum perforatum (st. john's wort) in tablet form
KR890001559A (ko) 트라피딜을 함유하는 제약 조성물, 그의 제조방법 및 관련된 치료 용도
AU2003285739B2 (en) Extended release venlafaxine tablet formulation

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20100630

Year of fee payment: 15

EXPY Expiration of term